Trend Reporting (MDR/MIR)
Obligation to report statistically significant increases in expected non-serious incidents.
Definition
EU MDR Article 88 requires trend reporting when expected adverse events show a clinically significant increase. Sponsors define the trend signals, thresholds, and analysis frequency in the PMS plan. Trend reports cover incidents that are not serious incidents and expected undesirable side effects that could significantly affect the benefit-risk analysis, when their frequency or severity increases significantly. Manufacturers must define how they detect a statistically significant increase, the observation period and thresholds, in the PMS plan. Reports are submitted through EUDAMED using the manufacturer trend report form.What this means in practice
Trend reporting closes the gap between routine vigilance (per-event) and PMS evaluation (periodic) - and is one of the more difficult areas for PRRCs to operationalize.Examples
- A manufacturer of an implantable medical device reports an unusual increase in the number of patient complaints related to minor allergic reactions, even though individual reactions are not severe enough to be considered serious incidents.
- A diagnostic software manufacturer observes a statistically significant rise in false-positive rates over a three-month period, which, while not immediately harmful, could lead to incorrect medical decisions if the trend continues.
- A company producing surgical instruments identifies an increasing pattern of reported minor malfunctions during procedures, indicating a potential manufacturing defect not previously flagged as a serious issue.
- •A common pitfall is failing to establish clear, objective trend signals and thresholds in the PMS plan, leading to subjective interpretations and inconsistent reporting.
- •Manufacturers often struggle with integrating trend reporting data effectively from various sources, such as complaint handling, vigilance, and clinical follow-up activities.
- •One mistake is not adequately documenting the rationale for chosen trend thresholds, which can lead to difficulties during regulatory audits.
- •Another pitfall is delaying the aggregation and analysis of post-market data, which can result in missing critical trends until it is too late to act proactively.
- •Failing to allocate sufficient resources, including personnel and appropriate software tools, for continuous trend analysis is a frequent oversight.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Post-Market
· Same categoryExpedited FDA MDR for events requiring remedial action to prevent unreasonable risk of substantial harm.
Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status.
Communication to users notifying them of a safety issue, corrective action, or important product information.
FDA's mandatory electronic submission system for Medical Device Reports.
Where this term appears across MedTech Terms.
Latest in MedTech
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 1MDR Article 88Tier 1 VerifiedEUR-Lexeur-lex.europa.eu
- 2EUDAMED Public SiteTier 2 VerifiedEuropean Commissionec.europa.eu
- 3MDCG Vigilance GuidanceTier 2 VerifiedMDCGhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.